表4_伊立替康盐酸脂质体联合5-氟尿嘧啶和亚叶酸钙治疗局部晚期或转移性胰腺导管腺癌的成本效益分析

数据集获取（Figshare）

• 源站标题：Table 4_Cost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma.xlsx
• DOI：10.3389/fphar.2025.1596658.s004
• 发布日期：2025-11-12
• 文件数：1 个
• 文件总体积：10.44 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_4_Cost-effectiveness_analysis_of_irinotecan_hydrochloride_liposome_in_combination_with_5-fluorouracil_and_leucovorin_in_locally_advanced_or_metastatic_pancreatic_ductal_adenocarcinoma_xlsx/30596237

命令行下载

curl -L -o "Table 4_Cost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in locally advanced or meta.xlsx" "https://ndownloader.figshare.com/files/59490476"

文件清单

• Table 4_Cost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in locally advanced or meta.xlsx（10.44 KB）

文件总体积 10.44 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ObjectiveThis study aims to evaluate the cost-effectiveness of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin (5-FU/LV) as a second-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma, from the perspective of the healthcare system in China.
MethodsA partitioned survival model was developed based on data from PAN-HEROIC-1 clinical trial (NCT05074589) and relevant literature. The simulation horizon was set at 5 years, with a cycle length of 2 weeks. Costs and utility values were discounted at an annual rate of 5%. Quality-adjusted life years (QALYs) served as the primary outcome measure, and the incremental cost-effectiveness ratio was calculated to compare irinotecan hydrochloride liposome plus chemotherapy regimen (experimental group) with the 5-FU/LV regimen (control group). One-way sensitivity analysis and probabilistic sensitivity analysis were performed to assess the robustness of the results.
ResultsThe results revealed that the ICER for the experimental group compared to the control group was ¥1,271,796.38/QALY, exceeding the willingness-to-pay (WTP) threshold of three times China’s per capita gross domestic product (GDP) in 2023. One-way sensitivity analysis indicated that parameters such as utility value during progression-free survival, body surface area, the cost of irinotecan hydrochloride liposome and the utility value during disease progression significantly influenced the model outcomes. Probabilistic sensitivity analysis demonstrated that the probability of the irinotecan hydrochloride liposome being cost-effective was 0.
ConclusionWhen using three times per capita GDP of China in 2023 as the WTP threshold, the irinotecan hydrochloride liposome plus chemotherapy regimen is not considered cost-effective compared to the standard 5-FU/LV regimen.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fphar.2025.1596658.s004（source: https://frontiersin.figshare.com/articles/dataset/Table_4_Cost-effectiveness_analysis_of_irinotecan_hydrochloride_liposome_in_combination_with_5-fluorouracil_and_leucovorin_in_locally_advanced_or_metastatic_pancreatic_ductal_adenocarcinoma_xlsx/30596237）。